IL301596A - Pharmacy composition - Google Patents

Pharmacy composition

Info

Publication number
IL301596A
IL301596A IL301596A IL30159623A IL301596A IL 301596 A IL301596 A IL 301596A IL 301596 A IL301596 A IL 301596A IL 30159623 A IL30159623 A IL 30159623A IL 301596 A IL301596 A IL 301596A
Authority
IL
Israel
Prior art keywords
mitapivat
amount
pediatric subject
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL301596A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL301596A publication Critical patent/IL301596A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL301596A 2020-09-25 2021-09-24 Pharmacy composition IL301596A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US202163238483P 2021-08-30 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IL301596A true IL301596A (en) 2023-05-01

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301596A IL301596A (en) 2020-09-25 2021-09-24 Pharmacy composition

Country Status (10)

Country Link
US (1) US20230338283A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542701A (cg-RX-API-DMAC7.html)
KR (1) KR20230074536A (cg-RX-API-DMAC7.html)
AU (1) AU2021347349B2 (cg-RX-API-DMAC7.html)
CA (1) CA3196829A1 (cg-RX-API-DMAC7.html)
IL (1) IL301596A (cg-RX-API-DMAC7.html)
MX (1) MX2023003431A (cg-RX-API-DMAC7.html)
TW (1) TW202228691A (cg-RX-API-DMAC7.html)
WO (1) WO2022067039A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) * 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태

Also Published As

Publication number Publication date
AU2021347349A1 (en) 2023-06-08
MX2023003431A (es) 2023-05-12
AU2021347349B2 (en) 2026-08-13
EP4216956A1 (en) 2023-08-02
TW202228691A (zh) 2022-08-01
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
WO2022067039A1 (en) 2022-03-31
US20230338283A1 (en) 2023-10-26
JP2023542701A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
IL295459A (en) Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL257276A (en) Methods for treating Knox-Gestaut syndrome using penforamine
Sival et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial
IL290727B2 (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
IL275115B2 (en) Bis-choline tetrathiolmolybdate for the treatment of Wilson's disease
IL301910A (en) Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
Lechin et al. Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: A double‐blind, crossover placebo‐controlled study
IL281793B (en) Use of cannabinoids in the treatment of epilepsy
IL297642A (en) Methods for using t-type calcium channel modulators
IL283069B1 (en) Methods of administering corticosteroids
US20190000820A1 (en) Durable Treatment with 4-Aminopyridine in Patients with Demyelination
IL279220B2 (en) Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
IL303117A (en) Preparations containing flumazenil and naltrexone and methods of using them
IL266114B2 (en) A preparation containing anti-Abeta protiferyl antibody and BETA-SECRETASE inhibitor BACE1 for the treatment of Alzheimer's disease
IL292367A (en) Methods for treating the symptoms of autism spectrum disorder
Nevmerzhitskaya et al. Short-term safety and efficacy of Onasemnogene Abeparvovec in 10 patients with Spinal Muscular Atrophy: Cohort study
IL302718A (en) A tablet for use in the treatment of Huntington's disease and a method for its preparation
IL301088A (en) Ribitol treatment
IL297218A (en) Pharmaceutical formulations
QIN et al. Development of novel therapies for Huntington's disease: hope and challenge 1
US20230338283A1 (en) Pharmaceutical formulation
CN116568281A (zh) 药物制剂
Ross et al. P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria
IL292982A (en) Methods of Administering Voxlotor
IL324041A (en) Methods of treating hepatic-only metastatic uveal melanoma